Lumos Pharma, Inc. (LUMO)
Dec 12, 2024 - LUMO was delisted (reason: acquired by Double Point Ventures)
4.340
0.00 (0.00%)
Inactive · Last trade price
on Dec 11, 2024
Lumos Pharma Revenue
Lumos Pharma had revenue of $726.00K in the quarter ending September 30, 2024, with 10,271.43% growth. This brings the company's revenue in the last twelve months to $2.21M, up 26.94% year-over-year. In the year 2023, Lumos Pharma had annual revenue of $2.05M with 34.67% growth.
Revenue (ttm)
$2.21M
Revenue Growth
+26.94%
P/S Ratio
16.06
Revenue / Employee
$66,818
Employees
33
Market Cap
37.54M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLUMO News
- 1 year ago - Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma - GlobeNewsWire
- 1 year ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Lumos Pharma, Inc. - PRNewsWire
- 1 year ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MMLP and LUMO on Behalf of Shareholders - PRNewsWire
- 1 year ago - Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024 - GlobeNewsWire
- 1 year ago - Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 1 year ago - Lumos Pharma, Inc. (LUMO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update - GlobeNewsWire
- 1 year ago - Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024 - GlobeNewsWire